PDCD1 and melanoma: Vidutolimod plus pembrolizumab demonstrated tolerability in patients with PD‐1 blockade–resistant melanoma, as supported by the incidence of grade ≥3 AEs and severe immune‐mediated AEs and the absence of treatment‐related deaths.